Traditional uses of plants in the Eastern Riviera (Liguria, Italy).

AIM OF THE STUDY: The aim of the present study was to explore the traditional plant knowledge of a zone of the Ligurian coast, known as Riviera spezzina (RS), Eastern Liguria, Italy. MATERIALS AND METHODS: Ethnobotanical information was obtained through open informal interviews. The informants were residents, belonging to families living in the study area since generations, and involved, at least partially, in agriculture. RESULTS AND CONCLUSIONS: A total of 120 botanical taxa were recorded. Ethnobotanical data included medicinal (40.4%), alimentary (46.5%), veterinary (4.6%), domestic and cosmetic (4.3%), magic and ritual (1.8%) and other uses (2.4%). Medicinal plants are used to treat a wide range of diseases, mainly disorders of digestive system, skin, and genital-urinary and respiratory traits. The key role played by undomesticated edible herbs, locally known as "erbette", in traditional cooking recipes of RS was shown. These botanicals are rich in bioactive compounds, such as polyphenols, vitamins, complex sugars, essential fatty acids and fibers, and therefore might offer a valid protection against pathological conditions. Plant uses by RS people were compared with previous ethnobotanical literature, concerning the neighbouring areas of Liguria. Our results highlight the role of the traditional use of plants in the maintenance of health and the prevention of chronic and age-related diseases.

Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care.

This randomised clinical trial, involving patients with advanced colorectal cancer, was carried out to compare the effectiveness of accelerated folinic acid (FA) plus 5-fluorouracil (5-FU) with that of the conventional regimen of 5-FU alone. Both regimens were administered with simulataneous supportive care. 185 patients were eligible: 94 were randomly allocated to receive FA 200 mg/m2 i.v. plus 5-FU 400 mg/m2 i.v. on days 1-5 every 3 weeks; and 91 to receive 5-FU 400 mg/m2 i.v. on days 1-5 every 4 weeks. The response rate was 33.3% in the accelerated FA/5-FU and 18.6% in the 5-FU arm (P = 0.045). Median survival was 13.5 months in the FA/5-FU arm and 7.5 months in the 5-FU arm (P = 0.039). Toxicity was mild and slightly more pronounced in the FA/5-FU arm (P = 0.078). This study indicates that, in patients with advanced colorectal cancer, accelerated chemotherapy with FA and 5-FU and simultaneous supportive care is capable of achieving a higher response rate and longer survival than conventional 5-FU alone, without severe toxicity.

Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.

BACKGROUND/AIMS: Colon cancer is one of the major health problems in industrialized countries, and its incidence appears to be increasing. Surgical resectability is the most important prognostic determinant, although despite apparently curative surgery, recurrent tumors are common. Metastatic disease cannot be cured, and thus, there is a need for better adjuvant therapies. METHODS: Two hundred and thirty-nine patients with surgically resected colon cancer in Dukes' stage B2 or C were randomly assigned to chemotherapy or observation alone to determine whether adjuvant chemotherapy could effectively reduce the rate of cancer recurrence. One hundred and twenty-one patients in stage B2 and 118 patients in stage C were enrolled in the study. Adjuvant treatment consisted of folinic acid 200 mg/m2, intravenously, plus 5-fluorouracil 400 mg/m2, intravenously, on days 1-5 every 4 weeks for 12 cycles. RESULTS: In stage B2, no significant difference between the adjuvant arm and the observation arm was noted. In stage C, adjuvant chemotherapy produced an advantage over observation in terms of a reduction in cancer recurrence rate with prolongation of a disease-free interval (P = 0.0016) and an improvement in overall survival (P = 0.0025). CONCLUSIONS: This study shows that folinic acid plus 5-fluorouracil adjuvant chemotherapy is effective in patients with surgically resected Dukes' stage C colon carcinoma.